• This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific advisors
    • Senior Leadership Team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • ASPIRE IPF Ph2b trial
    • Rare lung diseases
      • Buloxibutid (C21) – IPF
      • Almee – PF anxiety
      • Buloxibutid (C21) – PAH
    • Future ATRAG indications
    • Our drug discovery engine
  • Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SVE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Rights Issue, September 2024
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Företrädesemission September 2024
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Expanded Access Policy
logo
  • This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific advisors
    • Senior Leadership Team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • ASPIRE IPF Ph2b trial
    • Rare lung diseases
      • Buloxibutid (C21) – IPF
      • Almee – PF anxiety
      • Buloxibutid (C21) – PAH
    • Future ATRAG indications
    • Our drug discovery engine
Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SVE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Rights Issue, September 2024
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Företrädesemission September 2024
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Expanded Access Policy
logo
Home / Investerare (SE) / Bolagsstyrning / Bolagsstruktur
Översikt Pressmeddelanden Företrädesemission September 2024
  • Aktien
    • Aktien
    • Aktieägare
    • Ägande styrelse och ledning
    • Aktiekapitalets utveckling
    • Emissioner
    • Analytiker
    • Listningsprospekt
Finansiella rapporter Finansiell kalender Events & Presentationer
  • Bolagsstyrning
    • Bolagsstyrningsrapporter
    • Bolagsstämma
    • Valberedning
    • Styrelsen
    • Revisionsutskott
    • Ersättningsutskott
    • Vetenskapligt utskott
    • Ledning
    • Arvoden och ersättningar
    • Revisorer
    • Bolagsordning
Bildbank Prenumerera på nyheter Investerarkontakt

Bolagsstruktur

logo
Vicore Pharma’s offices

Kornhamnstorg 53
SE-111 27 Stockholm, Sweden

Agern Allé 5A
DK-2970 Hørsholm, Denmark

Cambridge Innovation Center
14th floor, One Broadway, Cambridge
MA 02142, USA

We'd love to hear from you!
Phone: +46 (0) 31 788 05 60 Mail: info@vicorepharma.com
Billing and mailing address:

Vicore Pharma
Postbox 14
414 52 Gothenburg, Sweden

Quick links
Contact Subscribe to press releases Privacy Policy Cookies